Quinn M K, Edmond Karen M, Fawzi Wafaie W, Hurt Lisa, Kirkwood Betty R, Masanja Honorati, Muhihi Alfa J, Newton Sam, Noor Ramadhani A, Williams Paige L, Sudfeld Christopher R, Smith Emily R
Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Department of Women and Children's Health, Kings College London, United Kingdom.
Vaccine. 2022 Jun 15;40(27):3737-3745. doi: 10.1016/j.vaccine.2022.04.082. Epub 2022 May 23.
Vaccines may induce non-specific effects on survival and health outcomes, in addition to protection against targeted pathogens or disease. Observational evidence suggests that infant Baccillus Calmette-Guérin (BCG) vaccination may provide non-specific survival benefits, while diphtheria-tetanus-pertussis (DTP) vaccination may increase the risk of mortality. Non-specific vaccine effects have been hypothesized to modify the effect of neonatal vitamin A supplementation (NVAS) on mortality.
22,955 newborns in Ghana and 31,999 newborns in Tanzania were enrolled in two parallel, randomized, double-blind, placebo-controlled trials of neonatal vitamin A supplementation from 2010 to 2014 and followed until 1-year of age. Cox proportional hazard models were used to estimate associations of BCG and DTP vaccination with infant survival.
BCG vaccination was associated with a decreased risk of infant mortality after controlling for confounders in both countries (Ghana adjusted hazard ratio (aHR): 0.51, 95% CI: 0.38-0.68; Tanzania aHR: 0.08, 95% CI: 0.07-0.10). Receiving a DTP vaccination was associated with a decreased risk of death (Ghana aHR: 0.39, 95% CI: 0.26-0.59; Tanzania aHR: 0.19, 95% CI: 0.16-0.22). There was no evidence of interaction between BCG or DTP vaccination status and infant sex or NVAS.
We demonstrated that BCG and DTP vaccination were associated with decreased risk of infant mortality in Ghana and Tanzania with no evidence of interaction between DTP or BCG vaccination, NVAS, and infant sex. Our study supports global recommendations on BCG and DTP vaccination and programmatic efforts to ensure all children have access to timely vaccination.
Ghana (Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12610000582055) and Tanzania (ANZCTR: ACTRN12610000636055).
疫苗除了能预防特定病原体或疾病外,还可能对生存和健康结果产生非特异性影响。观察性证据表明,婴儿卡介苗(BCG)接种可能带来非特异性的生存益处,而白喉-破伤风-百日咳(DTP)疫苗接种可能增加死亡风险。有假设认为,疫苗的非特异性作用会改变新生儿维生素A补充剂(NVAS)对死亡率的影响。
2010年至2014年,在加纳的22955名新生儿和坦桑尼亚的31999名新生儿中开展了两项平行、随机、双盲、安慰剂对照的新生儿维生素A补充剂试验,并随访至1岁。采用Cox比例风险模型估计BCG和DTP疫苗接种与婴儿生存之间的关联。
在两个国家,校正混杂因素后,BCG疫苗接种与婴儿死亡风险降低相关(加纳校正风险比(aHR):0.51,95%置信区间:0.38-0.68;坦桑尼亚aHR:0.08,95%置信区间:0.07-0.10)。接种DTP疫苗与死亡风险降低相关(加纳aHR:0.39,95%置信区间:0.26-0.59;坦桑尼亚aHR:0.19,95%置信区间:0.16-0.22)。没有证据表明BCG或DTP疫苗接种状态与婴儿性别或NVAS之间存在相互作用。
我们证明,在加纳和坦桑尼亚,BCG和DTP疫苗接种与婴儿死亡风险降低相关,没有证据表明DTP或BCG疫苗接种、NVAS和婴儿性别之间存在相互作用。我们的研究支持关于BCG和DTP疫苗接种的全球建议以及确保所有儿童都能及时接种疫苗的规划工作。
加纳(澳大利亚新西兰临床试验注册中心(ANZCTR):ACTRN12610000582055)和坦桑尼亚(ANZCTR:ACTRN12610000636055)。